Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Approximately 10-20% of patients experience ongoing symptoms despite having received standard
antibiotic therapy for Lyme disease. Possible explanations for persistent symptoms include
persistent infection and/or post-infectious causes. Recent in vitro studies indicate that
disulfiram is effective at killing both the actively replicating and the more quiescent
persister forms of Borrelia burgdorferi, the microbe that causes Lyme Disease. In this study,
the investigators are examining the safety of disulfiram among patients with post-treatment
Lyme disease symptoms. The investigators are also conducting a preliminary investigation
regarding the relative benefit of 4 vs 8 weeks of treatment with disulfiram.